BriaCell Phase 2 breast cancer study shows 13.5-month median overall survival vs 6.7-9.8 months literature

BriaCell Therapeutics Corp.

Median overall survival 13.5 months in BriaCell's Phase 2 study vs 6.7-9.8 months for similar advanced metastatic breast cancer patients in literature.
21 of 29 patients treated since 2022 remain alive, suggesting strong survival benefit with combination regimen.
No dose limiting toxicities reported; Phase 2 study fully enrolled with 46 heavily pre-treated patients (average 5 prior treatments).
Combination regimen of Bria-IMT™ with checkpoint inhibitors (pembrolizumab or retifanlimab-dlwr) shows tolerability and efficacy.
Data supports upcoming pivotal study in advanced breast cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.